William Blair Analysts Boost Earnings Estimates for CTNM

Contineum Therapeutics, Inc. (NASDAQ:CTNM) – Analysts at William Blair upped their Q3 2025 earnings estimates for Contineum Therapeutics in a report released on Wednesday, August 6th. William Blair analyst M. Minter now expects that the company will earn ($0.35) per share for the quarter, up from their prior forecast of ($0.42). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Contineum Therapeutics’ current full-year earnings is ($2.01) per share. William Blair also issued estimates for Contineum Therapeutics’ Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.79) EPS, Q1 2026 earnings at ($0.36) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.35) EPS, FY2026 earnings at ($1.43) EPS, FY2027 earnings at ($1.30) EPS, FY2028 earnings at ($1.25) EPS and FY2029 earnings at ($1.12) EPS.

Other equities analysts also recently issued research reports about the company. Royal Bank Of Canada restated an “outperform” rating and issued a $31.00 price objective on shares of Contineum Therapeutics in a report on Thursday, May 15th. Morgan Stanley dropped their price objective on Contineum Therapeutics from $25.00 to $20.00 and set an “overweight” rating on the stock in a report on Monday, May 19th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $22.50.

Contineum Therapeutics Stock Performance

NASDAQ:CTNM opened at $6.47 on Friday. The stock’s 50 day moving average price is $4.68 and its 200 day moving average price is $5.71. Contineum Therapeutics has a 52 week low of $3.35 and a 52 week high of $20.55. The company has a market capitalization of $167.38 million, a P/E ratio of -2.94 and a beta of 1.04.

Contineum Therapeutics (NASDAQ:CTNM) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06).

Hedge Funds Weigh In On Contineum Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio acquired a new position in Contineum Therapeutics during the first quarter valued at approximately $27,000. Legal & General Group Plc grew its holdings in Contineum Therapeutics by 74.0% during the fourth quarter. Legal & General Group Plc now owns 3,631 shares of the company’s stock valued at $53,000 after purchasing an additional 1,544 shares during the last quarter. Corebridge Financial Inc. grew its holdings in Contineum Therapeutics by 73.1% during the fourth quarter. Corebridge Financial Inc. now owns 5,215 shares of the company’s stock valued at $76,000 after purchasing an additional 2,202 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Contineum Therapeutics by 90.4% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,860 shares of the company’s stock valued at $86,000 after purchasing an additional 2,783 shares during the last quarter. Finally, Nuveen LLC acquired a new position in Contineum Therapeutics during the first quarter valued at approximately $93,000.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).